BioGenCell’s mission is to develop an innovative technology platform that will enable the rapid creation of easy-to-use and cost-effective treatments for a wide range of degenerative diseases using highly standardized therapies derived from adult stem cells.
Mr. Eyal Peleg, CPA, MBA
Mr. Peleg has over 25 years experience in growing and managing professional teams as a CEO. He is currently a consultant to both start-ups and established companies on the issues of strategic planning, business plans, long and short term contracts as well as financial and tax planning programs and controlling.
Prior to his CEO positions, Mr. Peleg was a senior partner in an accounting firm responsible for IPOs, evaluations, business plans and controlling. He is a director of several commercial and hi-tech companies and is a member of several national and industrial committees, in charge of national financial regulations.
Mr. Peleg is a certified CPA and holds an MBA degree (financing) from the Recanati Business School of Tel Aviv University, Israel.